Join Our Webinar: Imaging in Clinical Trials of Covid19, 20th April 2020

Join Our Webinar: Imaging in Clinical Trials of Covid19, 20th April 2020

Live Webinar – Seeing through the Uncertainty: Imaging of Covid19

Recent Bio-Pharma partnerships are focused on the development of vaccines and cures for patients with Covid19. This is the time to be specific and strategic with designing your trials and planning your resources.

IAG team and collaborators are inviting you to a live webinar, designed for the drug developers focused on the lung diseases and in particular Covid19.

Key discussions points:

  • Overview of clinical and imaging features of Covid19 patients;
  • Imaging in the drug trials of Covid19 and lung diseases;
  • Imaging biomarkers for drugs in development;
  • AI and modern infrastructure in relevance to Covid19 drug trials.

The session will begin with a joined talk by Dr. Faiq Shaikh, IAG’s Head of Research & Enterprise and Dr. Michael Andersen, IAG’s member of Scientific Advisory Board and Chairman of the Danish Lung Radiology Society, followed by a live Q&A with the audience.

Date and Time:

Monday, 20th April 2020, 11:00 ET / 16:00 GMT

Register here!

About the Webinar:

This webinar is organized by IAG, Image Analysis Group

In the midst of COVID-19, IAG’s imaging experts are sharing their knowledge on how imaging, AI and modern trial infrastructure can support drug development for lung diseases, specifically for Covid19. The webinar will cover the use of X-ray, CT, PET, immunoPET based imaging endpoints and their relevance in supporting understanding of the efficacy and safety novel therapeutic agents.

About Dr. Faiq Shaikh:

Dr. Faiq Shaikh is IAG’s Head of Research & Enterprise. His background is in medical imaging and informatics. He is a physician with deep expertise in the use of molecular imaging, novel tracers and radiomics in clinical studies. Faiq is closely working with the world-class academic centres, biotechnology and pharmaceutical companies bringing predictive analytics and AI-based outcomes measures to drug development and clinical decision making.

About Dr. Michael Brun Andersen:

Dr. Andresen is a IAG’s Scientific Advisory Board and Chairman of the Danish Lung Radiology Society, expert in imaging and AI for lung diseases.

About IAG:

IAG is a strategic partner to bio-pharmaceutical companies developing new treatments to improve patients’ lives. We fuse decades of therapeutic insights, risk-sharing business model and agile culture to accelerate novel drug development. IAG broadly leverages its core imaging expertise, proprietary technology platform DYNAMIKA and capabilities to support an objective early go no/ go decision and drive excellence for tomorrow’s innovative therapeutic agents with speed.

Questions or need held registering, please email < >